Announcement Regarding Issuance of A Shares to Specific Objects, Associated Transaction Matters, and Conditional Share Subscription Agreement (Revised Draft)

Yunnan Wason Bio-technology Co., Ltd.

Announcement Regarding Issuance of A Shares to Specific Objects, Associated Transaction Matters, and Conditional Share Subscription Agreement (Revised Draft)

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and are free of any false records, misleading statements, or material omissions.

Important Reminder:

1. Yunnan Wason Bio-technology Co., Ltd. (hereinafter referred to as the "Company" or "Wason Bio-technology") reviewed and approved at the seventh meeting of the sixth Board of Directors, adjusted the total amount of capital to be raised, the pricing benchmark date, the issuance price, and the number of shares to be issued for the issuance of shares to specific objects in 2026 (hereinafter referred to as the "Current Issuance"). For details, please refer to the "Announcement on Adjusting the Total Amount of Capital Raised and Adjusting the Issuance Plan for the Issuance of A Shares to Specific Objects in 2026 by Yunnan Wason Bio-technology Co., Ltd." (Announcement No.: 2026-064) disclosed by the Company on the Juchao Information Network (www.cninfo.com.cn) on August 4, 2026. On August 3, 2026, the Company signed the "Conditional Share Subscription Agreement (Revised Draft) for the Issuance of A Shares to Specific Objects by Yunnan Wason Bio-technology Co., Ltd. and Beijing Tengyun Xinwo Bio-technology Partnership (Limited Partnership)" (hereinafter referred to as the "Conditional Share Subscription Agreement (Revised Draft)") with Beijing Tengyun Xinwo Bio-technology Partnership (Limited Partnership) (hereinafter referred to as "Tengyun Xinwo"). Tengyun Xinwo agreed to subscribe for all the shares issued by the Company in accordance with the relevant provisions of the "Conditional Share Subscription Agreement (Revised Draft)".

2. The issuance matters are subject to approval by the Company's shareholders' meeting, review by the State Administration for Market Regulation for business operator concentration filing (if required), review by the Shenzhen Stock Exchange, and registration with the China Securities Regulatory Commission (hereinafter referred to as the "CSRC"). Implementation is contingent upon approval from other necessary administrative approval authorities (if applicable). There is uncertainty as to whether the issuance will obtain approval from relevant regulatory authorities and the timing of such approval.

3. This associated transaction does not constitute a major asset restructuring as defined by the "Measures for the Administration of Major Asset Restructuring of Listed Companies," nor does it constitute a restructuring of the listed company.